Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study Evaluating the Safety and Efficacy of Topical Administration of WP1220, an Inhibitor of STAT3 Activation, in Adults With Stage I, II, or III Mycosis Fungoides (Cutaneous T-Cell Lymphoma, CTCL)

NCT04702503 is registered in ClinicalTrials.gov with Moleculin Biotech, Inc. as lead sponsor.

NCT NCT04702503
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04702503 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study Evaluating the Safety and Efficacy of Topical Administration of WP1220, an Inhibitor of STAT3 Activation, in Adults With Stage I, II, or III Mycosis Fungoides (Cutaneous T-Cell Lymphoma, CTCL)
Lead sponsor
Moleculin Biotech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
March 8, 2019
Completion date
November 15, 2020
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous t-cell lymphoma/mycosis fungoides